

Please type a plus sign (+) inside this box → 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

		Application Number	09/155,590
		Filing Date	September 30, 1998
		First Named Inventor	Jeffrey SCHLOM et al.
		Group Art Unit	1644
		Examiner Name	G. Ewoldt
Total Number of Pages in This Submission		Attorney Docket Number	38163-0061

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<b>Response to Notice of Non-Compliant Amendment; copy of Notice of Non-Compliant Amendment</b>
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

RECEIVED

FEB 10 2003

TECH CENTER 1600/2900

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name		
Signature		
Date	February 6, 2003	

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name		
Signature		Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



26633

PATENT TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
9155590	9/30/99	Schlum et al.	38165-0061

JOHN P ISACSON, ESQUIRE  
HELLER EHRLICH WHITE & MCAULIFFE  
1666 K STREET NW  
SUITE 300  
WASHINGTON DC 20006

EXAMINER	
ART UNIT	PAPER NUMBER
	33

DATE MAILED: 1/14/03

Please find below a communication from the EXAMINER in charge of this application  
Commissioner of Patent

**Notice of Non-Compliant Amendment (37 CFR 1.121)**

The amendment filed on 4/22/02, is considered non-compliant because it has not been submitted in the format required under 37 CFR 1.121, as amended on September 8, 2000 (see 65 Fed. Reg. 64603, Sept. 8, 2000, and 1238 O.G. 77, Sept. 19, 2000).

- 1. The amendment does not include a clean version of the replacement paragraph(s)/section(s). 37 CFR 1.121(h)(1)(ii).
- 2. The amendment does not include a marked-up version of the replacement paragraph(s)/section(s). 37 CFR 1.121(b)(1)(iii).
- 3. The amendment does not include a clean version of the amended claim(s). 37 CFR 1.121(c)(1)(i).
- 4. The amendment does not include a marked-up version of the amended claim(s). 37 CFR 1.121(c)(1)(ii).
- 5. Other: Amended claims must recite "(amended)" and the number of times amended. See MPEP Appendix, RULES.

Since the response appears to be bona fide, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner G.R. Ewoldt, Art Unit 1644, whose telephone number is 703-308-9805.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

G.R. Ewoldt, Ph.D.  
Patent Examiner  
December 30, 2002



Attorney Docket No.: 38163-0061

#34/F  
9/03

2/11/03

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**RECEIVED**

Applicant(s): Jeffrey SCHLOM et al. Confirmation No. 8846 FEB 10 2003  
Appl. No.: 09/155,590 Examiner: G. Ewoldt TECH CENTER 1600/2900  
Filing Date: September 30, 1998 Group Art Unit: 1644  
Title: MUTATED RAS PEPTIDES FOR GENERATION OF CD8+ CYTOTOXIC T LYMPHOCYTES

**RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT UNDER 37 CFR 1.121**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants herein respond to the Notice mailed January 14, 2003 (Paper No. 33).

Please amend the captioned application as set forth below. Applicants do not believe there is any fees due or any extension of time required with this filing, but hereby authorize payment if any is required, to firm deposit account no. 08-1641.

**IN THE CLAIMS**

Please amend claim 34 as set forth below.

---

34. (5 times Amended) The Pharmaceutical composition according to claims 32 or 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.